Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of asundexian for prevention of ischemic stroke after non-cardioembolic ischemic stroke or high-risk TIA
2022-001067-27Phase 3Active
- Sponsor
- Bayer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Noncardioembolic stroke (NCES), transient ischaemic attack (TIA) and stroke comparing Asundexian with Placebo (2 arms). Primary endpoint: Time to first occurrence of ischemic stroke. Started Oct 2022; status: active.
02
Drugs
asundexian
03
Conditions
Noncardioembolic stroke (NCES)transient ischaemic attack (TIA)stroke
Beyond the preview
Go deeper on 2022-001067-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001067-27.